Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Polycystic Ovary Syndrome 8Neoplasm Metastasis 5Breast Neoplasms 5Neoplasms 3Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Obesity 2Multiple Myeloma 2Metabolic Diseases 2Leukemia, Lymphocytic, Chronic, B-Cell 2Insulin Resistance 2Infertility 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Weight Loss 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1TP53 Y220C Mutation 1Splenomegaly 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Mycosis Fungoides 1Mouth Neoplasms 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × TP53 Y220C Mutation × Metformin × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡